Last reviewed · How we verify
Rubriment (benzyl nicotinate)
Rubriment (generic name: benzyl nicotinate) is a benzyl nicotinate drug. It is currently in unknown development.
Benzyl nicotinate works by stimulating the release of nitric oxide, which causes blood vessels to dilate and improves blood flow.
Rubriment, also known as benzyl nicotinate, is a small molecule drug in the benzyl nicotinate class. Its exact target and mechanism of action are unknown, but it is believed to work by dilating blood vessels and improving blood flow. It is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to fully understand its safety and efficacy. As a result, it is not widely used in clinical practice.
At a glance
| Generic name | benzyl nicotinate |
|---|---|
| Drug class | benzyl nicotinate |
| Therapeutic area | Hematology |
| Phase | unknown |
Mechanism of action
Think of it like a key that unlocks the blood vessels, allowing them to relax and widen. This helps improve blood flow to the skin, which can be beneficial for people with certain skin conditions. By improving blood flow, benzyl nicotinate can help reduce inflammation and promote healing.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rubriment CI brief — competitive landscape report
- Rubriment updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Rubriment
What is Rubriment?
How does Rubriment work?
What is the generic name of Rubriment?
What drug class is Rubriment in?
What development phase is Rubriment in?
Related
- Drug class: All benzyl nicotinate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing